Tom Kotsimbos
Overview
Explore the profile of Tom Kotsimbos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
93
Citations
895
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Keating C, Yonker L, Vermeulen F, Prais D, Linnemann R, Trimble A, et al.
Lancet Respir Med
. 2025 Jan;
13(3):256-271.
PMID: 39756424
Background: The goal of cystic fibrosis transmembrane conductance regulator (CFTR) modulators is to reach normal CFTR function in people with cystic fibrosis. Vanzacaftor-tezacaftor-deutivacaftor restored CFTR function in vitro and in...
2.
Konstan M, Polineni D, Chmiel J, Bilodeau L, Middleton P, Matouk E, et al.
J Cyst Fibros
. 2024 Jul;
24(1):83-90.
PMID: 38987119
Background: Lung inflammation is associated with tissue damage in cystic fibrosis (CF). LAU-7b, a novel oral drug candidate, was shown to control inflammation and stabilize CFTR protein in the epithelial...
3.
Yu C, Kotsimbos T
Int J Mol Sci
. 2023 Feb;
24(4).
PMID: 36835487
The interplay between airway inflammation and infection is now recognized as a major factor in the pathobiology in cystic fibrosis (CF). A proinflammatory environment is seen throughout the CF airway...
4.
Ruseckaite R, Salimi F, Earnest A, Bell S, Douglas T, Frayman K, et al.
Sci Rep
. 2022 Nov;
12(1):19748.
PMID: 36396972
Survival statistics, estimated using data from national cystic fibrosis (CF) registries, inform the CF community and monitor disease progression. This study aimed to estimate survival among people with CF in...
5.
Anderson J, Tierney A, Miles C, Kotsimbos T, King S
Nutr Health
. 2022 Nov;
30(4):697-706.
PMID: 36366805
Probiotics are used by people with cystic fibrosis (CF) and other chronic diseases to manage gastrointestinal symptoms. To describe probiotic knowledge; its relationship with probiotic use, probiotic information sources and...
6.
Cheng A, Dwyer D, Holmes M, Irving L, Simpson G, Senenayake S, et al.
Commun Dis Intell (2018)
. 2022 Apr;
46.
PMID: 35469560
Influenza is a common cause of acute respiratory infection, and is a major cause of morbidity and mortality. This report summarises the epidemiology of hospitalisations with laboratory-confirmed influenza during the...
7.
Begum H, Dwyer D, Holmes M, Irving L, Simpson G, Senenayake S, et al.
Commun Dis Intell (2018)
. 2022 Apr;
46.
PMID: 35382711
Introduction: Influenza is a common cause of acute respiratory infection, and is a major cause of morbidity and mortality. Coronavirus disease 2019 (COVID-19) is an acute respiratory infection that emerged...
8.
Anderson J, Tierney A, Miles C, Kotsimbos T, King S
J Hum Nutr Diet
. 2022 Jan;
35(3):444-454.
PMID: 35092114
Background: Cystic fibrosis (CF) primarily affects the lung, however, gastrointestinal disorders and symptoms, including dysbiosis, also impact on morbidity and quality of life. There is interest in strategies to modulate...
9.
Kotsimbos T, Kaye D, Keating D
Eur Respir J
. 2021 Nov;
58(5).
PMID: 34824129
No abstract available.
10.
Button B, Wilson L, Burge A, Kimmel L, Finlayson F, Williams E, et al.
ERJ Open Res
. 2021 Sep;
7(3).
PMID: 34549047
Background: Quality of life has improved dramatically over the past two decades in people with cystic fibrosis (CF). Quantification has been enabled by patient-reported outcome measures (PROMs); however, many are...